BFM
FULC icon

Boothbay Fund Management’s Fulcrum Therapeutics FULC Stock Holding History

Boothbay Fund Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,900
Closed -$1.31M – 1968
2025
Q2 		$1.31M Buy
+190,900
New +$1.02M 0.03% 604
2024
Q4 		– Sell
-129,100
Closed -$461K – 1646
2024
Q3 		$461K Buy
+129,100
New +$958K 0.01% 1017
2022
Q3 		– Sell
-24,100
Closed -$118K – 2357
2022
Q2 		$118K Buy
+24,100
New +$236K ﹤0.01% 1940

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Boothbay Fund Management's FULC Position: Q2 2026 in Review

Boothbay Fund Management held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 303,988 shares worth $1.11M. The position accounts for 0.01% of the portfolio, ranked #1025.

Boothbay Fund Management first reported a position in FULC in Q4 2020 and has held it in 12 quarters since. The position peaked at $6.24M in Q3 2025. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Boothbay Fund Management held 303,988 shares of Fulcrum Therapeutics worth $1.11M as of Q2 2026.
  • Boothbay Fund Management left its Fulcrum Therapeutics share count unchanged in Q2 2026.
  • Fulcrum Therapeutics made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1025 holding.
  • Boothbay Fund Management first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • Boothbay Fund Management's Fulcrum Therapeutics position peaked at $6.24M in Q3 2025.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.